Physician profile
Jay Wayne Smith
NPI 1053577098
$2,478.56
in general payments reported to CMS, 2019-2025
11 companies · $979 in 2025
The $979 reported for 2025 was more than what 99% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $297 · 2024: $1,203 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,478.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,118.71 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $463.83 | 2023-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $298.20 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $165.44 | 2023-2024 | Dificid |
| Alexion Pharmaceuticals, INC. | $117.72 | 2025 | Ultomiris |
| Madrigal Pharmaceuticals | $100.91 | 2024-2025 | Resmetirom, Rezdiffra |
| Janssen Biotech, INC. | $98.48 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Intercept Pharmaceuticals, INC. | $50.25 | 2023-2025 | Ocaliva |
| Lilly USA, LLC | $29.71 | 2024-2025 | Omvoh |
| Evoke Pharma, INC. | $18.45 | 2025 | |
| Aimmune Therapeutics, INC. | $16.86 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.